Skip to content
TalkGuest talkBPSA

The Case for Considering Psychedelics as Psychotherapeutic Tools

Max Wolff

When
Tuesday, 19 January 2027
18:30
Where
Online via Zoom
Zoom link via WhatsApp

Abstract

Psychedelic treatments for mental health conditions such as depression are increasingly viewed as primarily drug-based interventions, with psychotherapy (often misrepresented as “psychological support”) playing only a supportive or even dispensable role. However, growing evidence suggests that psychological processes, including the relationship between patient and therapist and psychotherapeutic aspects of the psychedelic experience, are central to treatment success. Drawing on findings from a large clinical trial of psilocybin for depression, this talk will explore how psychedelics may be better understood as tools that enable or enhance psychotherapy rather than as treatments in their own right. Using an analogy with anesthetics, i.e., another class of adjunctive drugs that facilitate various treatments by exerting potent effects on consciousness, I will also discuss how this perspective could fit within existing drug regulation.

Live on Zoom only – there will be no recording this time.

About the speaker

Max Wolff

Max Wolff is a psychologist, psychotherapist and clinician-scientist at Humboldt University Berlin, Germany. His research bridges psychedelic and psychotherapy research and explores psychological change processes associated with altered states of consciousness. He has contributed as a researcher and therapist to several clinical trials in the field and is committed to advancing professional training programs in psychedelic therapy.

In cooperation with

Berlin Psychedelic Science Association Logo
Berlin Psychedelic Science Association

A joint lecture by the PSNG and the BPSA.

Further reading

  1. Wolff et al. (2025): “Reframing psychedelic regulation: Tools, not treatments”, Drug Science, Policy and Law.